First-line pembrolizumab plus chemotherapy for extensive-stage small-cell lung cancer: a United States-based cost-effectiveness analysis

First-line pembrolizumab plus chemotherapy for extensive-stage small-cell lung cancer: a United States-based cost-effectiveness analysis

Abstract Background The clinical trial of Keynote-604 showed that pembrolizumab plus chemotherapy could generate clinical benefits for extensive-stage small-cell lung cancer (ES-SCLC). We aim to assess the efficacy and cost of pembrolizumab combined with chemotherapy in the first-line treatment sett...

Full description

Bibliographic Details
Main Authors: Youwen Zhu, Huabin Hu, Dong Ding, Shuosha Li, Mengting Liao, Yin Shi, Jin Huang
Format: Article
Language:English
Published: BMC 2021-12-01
Series:Cost Effectiveness and Resource Allocation
Subjects:
Pembrolizumab
ES-SCLC
Platinum-etoposide
Cost-effectiveness
Quality-adjusted life-years
Online Access:https://doi.org/10.1186/s12962-021-00329-w

Similar Items

Similar Items